

10 May 2018
ASX Code: MXC

MGC Derma launches Second Derma Plus CBD Product

- MGC Derma launches its second Derma Plus product, CBD Herbal Replenish Cream, specifically developed for external skin care and relief from inflammatory skin conditions
- This is the second of three skincare products to be launched this year containing cannabidiol (CBD) compounds extracted from cannabis produced within the MGC Botanic division
- The Company expects to launch its third Derma Plus product, CBD Herbal Balm – for oily and acne prone skin later this year
- A study assessing the effect of CBD Herbal Replenish Cream concluded improvements in 86% of participants.

MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) is pleased to announce its European cosmetics subsidiary MGC Derma (MXC 51%), has today launched the CBD latest skincare product within its Derma Plus collection.

MGC Derma have expanded the Derma Plus range with the launch of CBD Herbal Replenish Cream, the second skincare product containing cannabidiol (CBD) compounds launched in 2018. MGC Derma Plus products are dermatologically tested, research backed, specifically designed to improve the natural defense of the skin and to stimulate the skin functions and regeneration.

This comes after the successful launch of the CBD Herbal Repair Cream, the first product within the Derma Plus range launched in January, which is developed for treating dry, sensitive and flaky skin.

MGC Derma Plus CBD Product Range

Products in the Derma Plus range have been specifically designed and formulated to use propriety Cannabidiol compounds extracted from the cannabis plant produced by the MGC Botanic division. Independent dermatological study in Europe in 2017 found that these compounds have shown to deliver strong improvements across a range of skin conditions.



A
S
X

R
E
L
E
A
S
E

This study independently assessed the cream on 24 volunteers over a 30 day period concluded that the following calculated values presented percentage improvement in skin condition on day 30 (dermatologist evaluation): “Dry skin; 71% improvement, flaking skin; 65% improvement, itching skin; 86% improvement. Due to the results, 92% of patients said they would continue using the tested cream¹”. Positive testing results conclude that the CBD Herbal Replenish cream provides the following treatment: improved skin appearance, smoothness and replenishment, reduction of dry and flaking skin and improvement in appearance of red, inflamed and sensitive skin* (65% after 4 weeks of evaluation)²”.

Roby Zomer, Co-founder and Executive Director/CEO, commented:

“We’re excited with our MGC Derma, the cosmetics subsidiary, progress and its Derma Plus products have now launched and are available to its base of global customers, for sale where legally permitted. MGC Derma Plus is a premium range designed to support the capacity for skin repair and prevent skin problems. The newest product will be a valuable addition to the range supporting our brand and increasing our presence within the CBD infused skincare space.”

-- Ends --

For further information, please contact:

Media Enquiries

Alex Liddington-Cox
Media and Capital Partners
+61 474 701 469
alex.liddingtoncox@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 6382 3390
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based specialist medical cannabis company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoids based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels



¹ MGC Derma Report

² MGC Derma Report